Literature DB >> 28522568

Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4.

David E Green1, Tamara C Murphy2, Bum-Yong Kang2, Brahmchetna Bedi2, Zhihong Yuan2, Ruxana T Sadikot2, C Michael Hart2.   

Abstract

Pulmonary hypertension (PH) is a progressive disorder whose cellular pathogenesis involves enhanced smooth muscle cell (SMC) proliferation and resistance to apoptosis signals. Existing evidence demonstrates that the tumor suppressor programmed cell death 4 (PDCD4) affects patterns of cell growth and repair responses in the systemic vasculature following experimental injury. In the current study, the regulation PDCD4 and its functional effects on growth and apoptosis susceptibility in pulmonary artery smooth muscle cells were explored. We previously demonstrated that pharmacological activation of the nuclear transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) attenuated hypoxia-induced proliferation of human pulmonary artery smooth muscle cells (HPASMCs) by inhibiting the expression and mitogenic functions of microRNA-21 (miR-21). In the current study, we hypothesize that PPARγ stimulates PDCD4 expression and HPASMC apoptosis by inhibiting miR-21. Our findings demonstrate that PDCD4 is reduced in the mouse lung upon exposure to chronic hypoxia (10% O2 for 3 wk) and in hypoxia-exposed HPASMCs (1% O2). HPASMC apoptosis was reduced by hypoxia, by miR-21 overexpression, or by siRNA-mediated PPARγ and PDCD4 depletion. Activation of PPARγ inhibited miR-21 expression and resultant proliferation, while restoring PDCD4 levels and apoptosis to baseline. Additionally, pharmacological activation of PPARγ with rosiglitazone enhanced PDCD4 protein expression and apoptosis in a dose-dependent manner as demonstrated by increased annexin V detection by flow cytometry. Collectively, these findings demonstrate that PPARγ confers growth-inhibitory signals in hypoxia-exposed HPASMCs through suppression of miR-21 and the accompanying derepression of PDCD4 that augments HPASMC susceptibility to undergo apoptosis.

Entities:  

Keywords:  pulmonary hypertension; smooth muscle cell proliferation

Mesh:

Substances:

Year:  2017        PMID: 28522568      PMCID: PMC5582937          DOI: 10.1152/ajplung.00532.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  46 in total

1.  Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.

Authors:  Seiichiro Sakao; Laimute Taraseviciene-Stewart; Jong Deog Lee; Kathy Wood; Carlyne D Cool; Norbert F Voelkel
Journal:  FASEB J       Date:  2005-05-16       Impact factor: 5.191

2.  PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.

Authors:  Xianghuai Lu; Tamara C Murphy; Mark S Nanes; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-09       Impact factor: 5.464

3.  Peroxisome Proliferator-Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling.

Authors:  Bum-Yong Kang; Kathy K Park; Jennifer M Kleinhenz; Tamara C Murphy; David E Green; Kaiser M Bijli; Samantha M Yeligar; Kristal A Carthan; Charles D Searles; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

Review 4.  MicroRNA-21: from cancer to cardiovascular disease.

Authors:  Virginija Jazbutyte; Thomas Thum
Journal:  Curr Drug Targets       Date:  2010-08       Impact factor: 3.465

Review 5.  Caspase-independent cell death: leaving the set without the final cut.

Authors:  S W G Tait; D R Green
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

6.  miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma.

Authors:  Lie-Hao Jiang; Ming-Hua Ge; Xiu-Xiu Hou; Jun Cao; Si-Si Hu; Xiao-Xiao Lu; Jing Han; Yi-Chen Wu; Xiang Liu; Xin Zhu; Lian-Lian Hong; Pei Li; Zhi-Qiang Ling
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

7.  SMAD proteins control DROSHA-mediated microRNA maturation.

Authors:  Brandi N Davis; Aaron C Hilyard; Giorgio Lagna; Akiko Hata
Journal:  Nature       Date:  2008-06-11       Impact factor: 49.962

8.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

Authors:  Erika L Lundgrin; Margaret M Park; Jacqueline Sharp; W H Wilson Tang; James D Thomas; Kewal Asosingh; Suzy A Comhair; Frank P DiFilippo; Donald R Neumann; Laura Davis; Brian B Graham; Rubin M Tuder; Iva Dostanic; Serpil C Erzurum
Journal:  Ann Am Thorac Soc       Date:  2013-02

Review 9.  Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4.

Authors:  Matthew R Young; Hsin-Sheng Yang; Nancy H Colburn
Journal:  Trends Mol Med       Date:  2003-01       Impact factor: 11.951

10.  Peroxisome proliferator-activated receptor gamma (PPARγ) regulates thrombospondin-1 and Nox4 expression in hypoxia-induced human pulmonary artery smooth muscle cell proliferation.

Authors:  David E Green; Bum-Yong Kang; Tamara C Murphy; C Micheal Hart
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

View more
  12 in total

1.  PPARγ Regulates Mitochondrial Structure and Function and Human Pulmonary Artery Smooth Muscle Cell Proliferation.

Authors:  Samantha M Yeligar; Bum-Yong Kang; Kaiser M Bijli; Jennifer M Kleinhenz; Tamara C Murphy; Gloria Torres; Alejandra San Martin; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2018-05       Impact factor: 6.914

2.  Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.

Authors:  Gexiang Cai; Jingjing Liu; Meibin Wang; Lihuang Su; Mengsi Cai; Kate Huang; Xiuchun Li; Manxiang Li; Liangxing Wang; Xiaoying Huang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

3.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 4.  Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Authors:  Georg Hansmann; Laurent Calvier; Michael G Risbano; Stephen Y Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

Review 5.  Genetic Delivery and Gene Therapy in Pulmonary Hypertension.

Authors:  Nabham Rai; Mazen Shihan; Werner Seeger; Ralph T Schermuly; Tatyana Novoyatleva
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 6.  Non-Coding RNA Networks in Pulmonary Hypertension.

Authors:  Hongbin Zang; Qiongyu Zhang; Xiaodong Li
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

7.  FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

Authors:  Meibin Wang; Lihuang Su; Junwei Sun; Luqiong Cai; Xiuchun Li; Xiayan Zhu; Lanlan Song; Jingyin Li; Shuolan Tong; Qinlian He; Mengsi Cai; Lehe Yang; Yanfan Chen; Liangxing Wang; Xiaoying Huang
Journal:  J Cell Mol Med       Date:  2022-01-06       Impact factor: 5.295

8.  Differential Expression Profile of microRNAs and Tight Junction in the Lung Tissues of Rat With Mitomycin-C-Induced Pulmonary Veno-Occlusive Disease.

Authors:  Qing Song; Ping Chen; Shang-Jie Wu; Yan Chen; Yan Zhang
Journal:  Front Cardiovasc Med       Date:  2022-02-16

9.  TransmiR v2.0: an updated transcription factor-microRNA regulation database.

Authors:  Zhan Tong; Qinghua Cui; Juan Wang; Yuan Zhou
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice.

Authors:  Xuguang Li; Feng Zhu; Weidong Meng; Feng Zhang; Jiang Hong; Guobing Zhang; Fang Wang
Journal:  J Cell Mol Med       Date:  2019-11-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.